Home/Browse by collection/Clinical/Translational Cancer Immunotherapy

Clinical/Translational Cancer Immunotherapy

Section Edited by Douglas G. McNeel, MD, PhD; Claudia Palena, PhD; and Jeffrey S. Weber, MD, PhD Clinical trials: prospective studies including first-in-man clinical trials, phase II/III clinical studies, and immune monitoring investigations. Small, single institution-based retrospective reports are discouraged. Preclinical studies: studies that lead to mechanistic understanding or novel development of agents and combination therapies directly relevant to human immunotherapy.

Showing results 81 - 90 of 100

Sorted by most recent

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817
Neal E Ready, Clarisse Audigier-Valette, Jonathan W Goldman, Enriqueta Felip, Tudor-Eliade Ciuleanu, María Rosario García Campelo, Kevin Jao, Fabrice Barlesi, Stéphanie Bordenave, Erika Rijavec, Laszlo Urban, Jean-Sébastien Aucoin, Cristina Zannori, Karim Vermaelen, Osvaldo Arén FronteraSee the full list of authors

1 February 2023

Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation
Viktoria Marquardt, Johanna Theruvath, David Pauck, Daniel Picard, Nan Qin, Lena Blümel, Mara Maue, Jasmin Bartl, Ulvi Ahmadov, Maike Langini, Frauke-Dorothee Meyer, Allison Cole, Joselyn Cruz-Cruz, Claus M Graef, Matthias WölflSee the full list of authors

13 January 2023